Crown Bioscience Launches CrownSyn

Crown Bioscience has announced the launch of a novel bioinformatics tool, CrownSyn. Its goal is to make it easier for researchers to understand drug combination effects, and is now available as an add-on feature to all two-drug combinatorial studies conducted by Crown Bioscience.

Combination therapies can improve efficacy, overcome drug resistance and decrease toxicity. Crown Bioscience’s team of bioinformaticians developed CrownSyn to help clients evaluate the efficacy of two-drug combinations. The company says that the tool helps clients visualize and characterize combination effects as synergistic, antagonistic, and additive as well as determine optimal doses for further safety and efficacy studies. 

CrownSyn is compatible with most experimental designs and provides dose-response curve graphs, combination index graphs, inhibition heat maps for concentration combinations, 2-D contour maps and 3D response surface plots. 

“Combination therapies are a cornerstone for the treatment of complex diseases like resistant and metastatic cancers, cardiovascular, metabolic and inflammatory diseases,” said Laurie Heilmann, Crown Bioscience’s chief business officer. “CrownSyn™ is CrownBio’s latest contribution to help our clients progress innovative drug development programs aimed at treating these complicated conditions with combination therapies.”